Sangeeta Manjhi¹, Tanu Engle¹, Pratibha Kanwar¹, Kamini Sonwani², Anjali¹, Harish Sharma³ and Gyanesh Kumar Sahu¹*

¹Rungta Institute of Pharmaceutical Sciences and Research, Kohka, Kurud, Bhilai, India
²Rungta Institute of Pharmaceutical Sciences, Kohka, Kurud, Bhilai, India
³School of Pharmacy, Anjaneya University, Raipur, India

*Corresponding Author: Dr. Gyanesh Kumar Sahu, Professor and Dean, Rungta Institute of Pharmaceutical Sciences and Research, Kohka, Kurud, Bhilai, India.

Received: November 29, 2024; Published: December 20, 2024

Abstract

Polycystic Ovarian Disease (PCOD) is a multifaceted endocrine disorder affecting women of reproductive age, characterized by hormonal imbalances, ovarian dysfunction, and metabolic complications. The condition's increasing prevalence underscores the need for a comprehensive understanding of its pathophysiology, clinical manifestations, and effective treatment modalities.

This review examines the underlying mechanisms of PCOD, including insulin resistance, hyperandrogenism, and chronic inflam mation, which contribute to its complex etiology. Conventional management strategies, such as hormonal therapy and lifestyle modi fications, are discussed alongside emerging alternatives, including herbal and nutraceutical interventions.

Particular emphasis is placed on the role of herbal remedies like Ashwagandha (Withania somnifera), Shatavari (Asparagus rac emosus), and Cinnamon (Cinnamomum cassia) in modulating hormonal levels, improving insulin sensitivity, and alleviating symp toms associated with PCOD. The safety, efficacy, and potential for integration of these natural therapies into conventional treatment regimens are critically analyzed.

Keywords: Polycystic Ovarian Disease

References

1. Burger CW., et al. “Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea”. The Journal of Clinical Endocrinology and Metabolism6 (1985): 1126-32.
2. Joshi A. “PCOD (Polycystic Ovarian Disease): A Review Article”. ECS Transactions1 (2022): 15973.
3. Hull MG. “Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies”. Gynecological Endocrinology3 (1987): 235-245.
4. Urman B., et al. “Pregnancy in infertile PCOD patients. Complications and outcome”. The Journal of Reproductive Medicine8 (1997): 501-505.
5. Anjali CS., et al. “PCOD in female reproductive age: A review”. World Journal of Pharmaceutical Research 1 (2019): 677-684.
6. Wardhan R. “Polycystic ovarian cyst disorder (PCOD): causes and control”. Best Practice and Research Clinical Obstetrics and Gynaecology 5 (2016): 685-706.
7. Wagh P., et al. “Early detection of PCOD using machine learning techniques”. In Artificial Intelligence and Speech Technology (2021): 9-20.
8. Yeh HC., et al. “Polycystic ovarian disease: US features in 104 patients”. Radiology1 (1987): 111-116.
9. Ardaens Y., et al. “Polycystic ovarian disease: contribution of vaginal endosonography and reassessment of ultrasonic diagnosis”. Fertility and Sterility6 (1991): 1062-1068.
10. Vikram S and HN SD. “Management of PCOD-A Case Report”. Journal of Ayurveda and Integrated Medical Sciences4 (2017): 291-295.
11. Hann LE., et al. “Polycystic ovarian disease: sonographic spectrum”. Radiology2 (1984): 531-534.
12. MIZUNUMA H., et al. “Serum immunoreactive inhibin levels in polycystic ovarian disease (PCOD) and hypogonadotropic amenorrhea”. Endocrine Journal4 (1994): 409-414.
13. Soumya V. “Polycystic Ovary Disease (PCOD)-An Insight into Rodent Models, Diagnosis and Treatments”. Journal of Clinical and Medical Images 11 (2021): 1-3.
14. Gadir AA., et al. “Implications of ultrasonically diagnosed polycystic ovaries. I. Correlations with basal hormonal profiles”. Human Reproduction4 (1992): 453-457.
15. Varghese R. “Health related complications associated with polycystic ovarian disease (PCOD)”. Pharma Innovation11 (2018): 86-90.
16. Kumari S. “Classification of pcos/pcod using transfer learning and gan architectures to generate pseudo ultrasound images (Doctoral dissertation, Dublin, National College of Ireland)” (2023).
17. Insler V., et al. “Polycystic ovaries in non-obese and obese patients: possible pathophysiological mechanism based on new interpretation of facts and findings”. Human Reproduction3 (1993): 379-384.
18. Shrestha A., et al. “Assessment of lifestyle and diet modification of patients suffering from polycystic ovarian disease (PCOD) in North India”. Journal of Food and Nutrition Sciences4 (2019): 60-65.
19. Anttila L., et al. “Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease”. Fertility and Sterility6 (1991): 1057-1061.
20. Kashyap S and Claman P. “Polycystic ovary disease and the risk of pregnancy-induced hypertension”. The Journal of Reproductive Medicine12 (2000): 991-994.
21. Urdl W. “Polycystic ovarian disease: endocrinological parameters with specific reference to growth hormone and somatomedin-C”. Archives of Gynecology and Obstetrics 243 (1988): 13-36.
22. Babore G. “Diagnosis of PCOD and the Diet to be taken”. International Journal of Collaborative Research on Internal Medicine and Public Health6 (2021): 1-2.
23. Orsini LF., et al. “Ultrasonic findings in polycystic ovarian disease”. Fertility and Sterility5 (1985): 709-714.
24. Bharathi K., et al. “Evaluation of indigenous drugs in the management of PCOD in teenage girls”. International Journal of Ayurveda and Pharma Research 3 (2013): 30-35.
25. Insler V and Lunenfeld B. “Polycystic ovarian disease: a challenge and controversy”. Gynecological Endocrinology1 (1990): 51-70.
26. Avhale SA and Avhale PS. “The management of Polycystic Ovarian Disease (PCOD) with the Vamana Karma-A Case Report”. Journal of Ayurveda and Integrated Medical Sciences5 (2020): 591-593.
27. Lanzone A., et al. “Polycystic ovary disease. A risk factor for gestational diabetes?”. The Journal of Reproductive Medicine4 (1990): 312-316.
28. BURGHEN GA., et al. “Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease”. The Journal of Clinical Endocrinology and Metabolism1 (1980): 113-116.
29. Bider D., et al. “Polycystic ovarian disease (PCOD)—Pregnancy rate and outcome in in vitro fertilization”. Journal of Assisted Reproduction and Genetics 10 (1993): 11-14.
30. Biggs JS. “Polycystic ovarian disease—current concepts”. Australian and New Zealand Journal of Obstetrics and Gynaecology1 (1981): 26-36.
31. Suikkari AM., et al. “Low levels of low molecular weight insulin-like growth factor-binding protein in patients with polycystic ovarian disease”. Human Reproduction2 (1989): 136-139.
32. Srinithi V and Rekha R. “Machine learning for diagnosis of polycystic ovarian syndrome (PCOS/PCOD)”. In2023 International Conference on Intelligent Systems for Communication, IoT and Security (ICISCoIS) (2023): 19-24.
33. Pandey A., et al. “A Review on Health Care Surveillance of PCOD”. Health 3 (2023): 03-15.
34. Grigoriou O., et al. “Low‐dose follicle‐stimulating hormone treatment for polycystic ovarian disease”. International Journal of Gynecology and Obstetrics1 (1996): 55-59.
35. Kaushik S and Mishra SK. “Comparative Analysis of Classification Methods for PCOD Prediction”. In 2023 14^th International Conference on Computing Communication and Networking Technologies (ICCCNT) (2023): 1-8.
36. Mahabeer S., et al. “Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease”. Hormone and metabolic research10 (1990): 537-540.
37. Bahçeci M., et al. “Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study”. The Journal of Reproductive Medicine2 (2005): 84-90.
38. Mahabeer S., et al. “Insulin and C-peptide secretion in non-obese patients with polycystic ovarian disease”. Hormone and Metabolic Research9 (1989): 502-506.
39. Awalekar J., et al. “Effect of Metformin in Patients of Polycystic Ovarian Disease (PCOD), a Comparative and Observational Study”. International Journal of Biomedical Research 6 (2015): 698-704.
40. Magotra A. “Management of PCOD wsr to Ayurvedic drugs and lifestyle”. Journal of Ayurveda and Integrated Medical Sciences5 (2020): 287-289.
41. Hooda M and Kumar B. “Ayurveda Management of Poly Cystic Ovarian Disease (PCOD)–A Case Report”. International Journal of AYUSH Case Reports2 (2023): 190-195.
42. Seyam E., et al. “Evaluation of tumor necrosis factor alpha serum level in obese and lean women with clomiphene citrate resistant polycystic ovary disease”. Middle East Fertility Society Journal3 (2017): 193-200.
43. Bates GW., et al. “Effect of body weight reduction on plasma androgens in obese, infertile women”. Fertility and Sterility4 (1982): 406-409.
44. Shirsath A., et al. “Study of oxidative stress and antioxidant levels in polycystic ovarian”. International Journal of Healthcare And Biomedical Research 4 (2015): 16-24.
45. Barbieri RL. “Polycystic ovarian disease”. Annual Review of Medicine 1 (1991): 199-204.
46. Begum MS and Areen S. “Optimizing Polycystic Ovarian Disorder (PCOD) Treatment with Personalized Lifestyle and Nutrition Strategies” (2023).
47. Wu TJ., et al. “Management of post-COVID-19 olfactory dysfunction”. Current Treatment Options in Allergy (2022): 1-8.
48. Pekonen F., et al. “Decreased 34K insulin-like growth factor binding protein in polycystic ovarian disease”. Fertility and sterility6 (1989): 972-975.
49. Tomar S. “Polycystic ovarian disease (PCOD)–calcarea carbonica patient”. Allgemeine Homöopathische Zeitung2 (2017): CM17-03.
50. Satyanarayana V., et al. “A review on PCOD in pregnant women’”. World Journal of Current Medical and Pharmaceutical Research (2019): 113-115.

Citation

Citation: Gyanesh Kumar Sahu., et al. “A Comprehensive Review of Polycystic Ovarian Disease (PCOD): Pathophysiology, Diagnosis, and Herbal Therapeutic Approaches". Acta Scientific Pharmaceutical Sciences 9.1 (2025): 70-81.

Copyright

Copyright: © 2025 Gyanesh Kumar Sahu., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.